Atabecestat

• CAT Number: I011876
• CAS Number: 1200493-78-2
• Molecular Formula: C18H14FN5OS
• Molecular Weight: 367.40
• Purity: ≥95%
• Synonyms: N-[3-[(4S)-2-Amino-4-methyl-4H-1,3-thiazin-4-yl]-4-fluorophenyl]-5-cyano-2-pyridinecarboxamide
• Target: Beta-secretase
• Storage: Store at 0-8 °C
• IC50: 0.010 μM
• IUPAC Name: N-[3-[(4S)-2-amino-4-methyl-1,3-thiazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide
• InChI: InChI=1S/C18H14FN5OS/c1-18(6-7-26-17(21)24-18)13-8-12(3-4-14(13)19)23-16(25)15-5-2-11(9-20)10-22-15/h2-8,10H,1H3,(H2,21,24)(H,23,25)/t18-/m0/s1
• InChIKey: VLLFGVHGKLDDLW-SFHVURJKSA-N
• SMILES: CC1(C=CSC(=N1)N)C2=C(C=CC(=C2)NC(=O)C3=NC=C(C=C3)C#N)F

Atabecestat(CAT: I011876) is a potent and selective β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, primarily used in neurological and Alzheimer’s disease research. By inhibiting BACE1, it prevents the production of amyloid-beta peptides, which are implicated in the formation of amyloid plaques—a hallmark of Alzheimer’s disease. Atabecestat supports studies on amyloidogenic pathways, disease progression, and therapeutic interventions aimed at mitigating cognitive decline. Its ability to cross the blood-brain barrier and selectively target BACE1 makes it a valuable tool for advancing research into the molecular mechanisms of neurodegeneration and potential treatments for Alzheimer’s and related disorders.